Welcome to our dedicated page for Centogene N.V. Common Shares news (Ticker: CNTG), a resource for investors and traders seeking the latest updates and insights on Centogene N.V. Common Shares stock.
This page provides an archive of news and press releases related to Centogene N.V. (historically associated with the symbol CNTG). The company has described itself as the essential life science partner for data-driven answers in rare and neurodegenerative diseases, integrating multiomic technologies with the CENTOGENE Biodatabank to support diagnosis and pharmaceutical research.
News items for Centogene cover several themes. These include announcements about large-scale research initiatives such as the Rostock International Parkinson's Disease (ROPAD) Study, which focuses on the genetics of Parkinson’s disease and has generated findings on genetic risk factors and the prevalence of specific variants. Releases also describe collaborations in lysosomal diseases and Gaucher disease, including work with partners like Critical Path Institute and Evotec SE, where CENTOGENE’s data and biomarkers have been used alongside external platforms to identify and characterize potential therapeutic candidates.
Other historical news highlights corporate and financial developments, such as strategic collaborations, joint ventures, financing arrangements, and the company’s strategic alternatives review. A key set of announcements in late 2024 and early 2025 detail the agreement and subsequent closing of the sale of Centogene N.V.’s operating subsidiaries to an affiliate of Charme Capital Partners, shareholder approvals at an Extraordinary General Meeting, and the company’s stated intention to enter dissolution and liquidation following the transaction.
Because Centogene N.V. has reported that, after the sale of its operating subsidiaries, it and its remaining subsidiary will no longer have operations and will enter dissolution and liquidation, the CNTG news flow is best understood as a historical record. Investors and researchers can use this page to review how the company described its multiomic diagnostics, Biodatabank, research collaborations, and the sequence of corporate events leading up to the sale of its operating subsidiaries and planned liquidation.
Centogene N.V. (Nasdaq: CNTG) will announce its financial results for Q3 2020 on December 16, 2020, at 8 a.m. EST, during a conference call. The company focuses on rare diseases, utilizing over 3.6 billion weighted data points from approximately 570,000 patients across 120 countries to improve treatment decisions and aid pharmaceutical partners in drug development. As of August 31, 2020, Centogene collaborates with over 40 pharmaceutical companies on 45 rare diseases, establishing a significant footprint in the global rare disease market.
Centogene and Alnylam Pharmaceuticals have launched a joint program named TRAMmoniTTR to conduct genetic screening for hereditary Transthyretin-related Amyloidosis (ATTRv). This initiative builds on the previous TRAM Study, which identified over 1% of 5,000 participants with ATTRv. The TRAMmoniTTR Study will monitor symptomatic and asymptomatic TTR-positive individuals for two years, using Centogene's biomarker profiling to enhance diagnostics. Experts from both companies emphasize the importance of early diagnosis and personalized treatment approaches.
Centogene N.V. (CNTG) has expanded its partnership with PTC Therapeutics to enhance genetic testing for Aromatic L-amino Acid Decarboxylase (AADC) deficiency across Europe, the Middle East, and Latin America. This initiative will provide free biochemical and genetic testing to patients enrolled in the REVEAL CP study, aimed at identifying AADC deficiency in individuals with cerebral palsy. The study utilizes CentoCard® blood samples to detect elevated 3-O-Methyldopa levels, critical for timely diagnosis and treatment options for this ultra-rare genetic disorder.
On November 13, 2020, CENTOGENE (Nasdaq: CNTG) announced the nomination of Dr. Jonathan G. Sheldon to the Supervisory Board, to be proposed at an Extraordinary General Meeting. Dr. Sheldon, Senior VP at QIAGEN, is recognized for his contributions to data interpretation in rare diseases. CENTOGENE focuses on transforming clinical and genetic data to assist in diagnosis and drug development for rare diseases, boasting a repository of over 3.6 billion data points from 570,000 patients across 120 countries.
Centogene (Nasdaq: CNTG) has partnered with Fujirebio Europe to enhance COVID-19 antigen testing using the LUMIPULSE® G technology, specifically in German airports. Fujirebio will supply LUMIPULSE G1200 instruments, enabling rapid results within 40 minutes from sample receipt. Centogene will manage sample collection via swabs and conduct analysis in their laboratories. The initial testing phase with Lufthansa starts November 12, offering free tests for select flights from Hamburg. This collaboration aims to improve COVID-19 testing capabilities and contribute to prevention efforts.
CENTOGENE has expanded its SARS-CoV-2 testing services to Berlin Brandenburg Airport (BER), marking its fourth major airport testing center in Germany. Passengers at BER, alongside the general public, can now access PCR tests from 7:00 a.m. to 7:00 p.m. without prior appointments. The initiative aims to facilitate safe travel during the COVID-19 pandemic, with results provided within 24 hours. CENTOGENE's test has received Emergency Use Authorization from the FDA, ensuring reliability and compliance with data privacy regulations.
Centogene N.V. (Nasdaq: CNTG) announces the departure of Prof. Arndt Rolfs as CEO effective October 20, 2020, with Dr. Andrin Oswald to take over on December 1, 2020. Prof. Rolfs will continue to advise during the transition. Dr. Oswald brings over 20 years of healthcare leadership experience, aiming to further expand Centogene's role in rare disease diagnostics. The company has developed a unique platform based on extensive real-world data, supporting improved clinical outcomes and drug development for rare diseases. Prof. Rolfs' leadership was instrumental in positioning the company for growth.
Centogene N.V. (Nasdaq: CNTG) has increased its full-year 2020 revenue guidance, projecting revenues above €80 million, up from a previous range of €60-65 million. This adjustment follows improved performance in their Covid-testing segment and a recovery in core business operations post-Q2 pandemic impacts. CFO Richard Stoffelen noted substantial growth in Covid-testing revenue and expressed optimism about continued business momentum. The company monitors its outlook closely as it aims to support health and safety globally.
Centogene N.V. (Nasdaq: CNTG) announced that the FDA has granted Emergency Use Authorization (EUA) for its new SARS-CoV-2 RT-PCR test, CentoSure. This test allows for screening individuals without COVID-19 symptoms, aiming to enhance widespread testing efforts in the U.S. and beyond. Prof. Arndt Rolfs, CEO, emphasized the importance of broad testing to curb virus spread. The assay has passed validation in their certified lab, indicating a commitment to quality and precision in COVID-19 diagnostics.
Centogene (Nasdaq: CNTG) has partnered with U-Diagnostics to enhance COVID-19 testing in the Netherlands amidst rising infection rates. This collaboration aims to address the current testing capacity shortage by leveraging Centogene's testing technologies, including the CentoSwab™ and RT-PCR analysis, to provide timely testing services. The partnership underscores the importance of innovative solutions to combat the pandemic. Both companies aim to facilitate accessible testing to protect community health and support economic stability.
FAQ
What is the current stock price of Centogene N.V. Common Shares (CNTG)?
What is the market cap of Centogene N.V. Common Shares (CNTG)?
